Clinical trial • Phase IV • Oncology
Tamoxifen for Myelofibrosis
Phase IV trial of Tamoxifen for Myelofibrosis. 14 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Myelofibrosis
- Trial Stage
- Phase IV
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 23-08-2025
- First CTIS Authorization Date
- 11-11-2025
Trial design
Phase IV trial across 1 site in Netherlands.
- Target Sample Size
- 14
Recruitment
- Planned Sample Size
- 14
- Recruitment Window Months
- 16
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 14
Netherlands
- Earliest CTIS Part Ii Submission Date
- 04-11-2025
- Latest Decision Or Authorization Date
- 11-11-2025
- Processing Time Days
- 7
- Number Of Sites
- 1
- Number Of Participants
- 14
Sites
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Hematology
- Principal Investigator Name
- Emanuele Ammatuna
- Principal Investigator Email
- e.ammatuna@umcg.nl
- Contact Person Name
- Emanuele Ammatuna
- Contact Person Email
- e.ammatuna@umcg.nl
Sponsor
Primary sponsor
- Full Name
- Universitair Medisch Centrum Groningen
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Investigational products
- Investigational Product Name
- Tamoxifen
- Active Substance
- Tamoxifen
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Investigational Product Name
- Ruxolitinib
- Active Substance
- Ruxolitinib
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.